NCT01290913已完成1 期
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
Lynda Schneider1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg)
研究概览
简要总结
This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.
详细描述
We hypothesize that pretreatment with anti-IgE mAb will greatly reduce the side effects and allergic reactions that occur during oral desensitization to peanut and will enhance the development of oral tolerance in patients with severe peanut allergy.
We will follow the patients for 5 years following study completion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with severe peanut allergy, between the ages of 7-25 years, having a history of significant clinical symptoms within 1 hr of peanut ingestion.
- •Total IgE >50 kU/L but <2,0000 kU/L.
- •Sensitivity to peanut will be documented by a positive skin prick test result and RAST test to peanut, with 20 kU/L as a lower limit for eligibility.
- •Patients must also fail a double blind food challenge with peanut at a dose of 100 mg or less (after a cumulative dose of 186 mg), with minimal or no reactions to the placebo challenge.
- •All female subjects of childbearing potential will be required to provide a urine sample for pregnancy testing that must be negative one week before being allowed to participate in the study.
- •Subjects must be planning to remain in the study area during the trial.
- •Subjects and/or their parents must be trained on the proper use of the Epi-Pen to be allowed to enroll in the study.
排除标准
- •Due to the risk of serious systemic anaphylactic reactions to peanut in this study, we will exclude:
- •Patients with acute infections, autoimmune disease, severe cardiac disease, and those who are treated with beta-adrenergic antagonistic drugs (beta-blockers, which increase the risk of more serious symptoms of anaphylaxis).
- •Subjects having a history of severe anaphylaxis to peanut requiring intubation or admission to an ICU, frequent urticaria, or history consistent with poorly controlled persistent asthma.
- •Total IgE > 2,000 IU/mL.
- •Subjects with unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that in the mind of the investigator might interfere with the evaluation or administration of the test drug or pose additional risk to the subject e.g. gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease.
- •Subject with an FEV1 or PEF less than 80% predicted with or without controller medication (if able to perform the maneuver) at screening, the oral desensitization visit, or food challenge visit.
- •Subjects who have received an experimental drug in the last 30 days prior to admission into this study or who plan to use an experimental drug during the study, who are current users of oral, intramuscular, or intravenous corticosteroids, or tricyclic antidepressants, or who are using medication that could induce adverse gastrointestinal reactions during the study.
- •Subjects refusing to sign the EpiPen Training Form.
- •Pregnant or breast-feeding females.
- •Subjects with severe food associated eczema, dermatitis herpetiformis, eosinophilic esophagitis, eosinophilic enteritis, proctocolitis, food protein induced enterocolitis syndrome (FPIES) or other gastrointestinal diseases. These requirements are necessary to limit the study to patients with primarily IgE mediated peanut allergy, and to exclude patients with peanut sensitivity mediated by cellular/T cell (non-IgE mediated) mechanisms.
研究组 & 干预措施
omalizumab, oral desensitization
Experimental
Patients receive omalizumab along with oral peanut desensitization.
干预措施: Omalizumab (Drug)
结局指标
主要结局
Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg)
时间窗: First day of desensitization
To tolerate refers to the ability of the patient to ingest the challenge dose of 500 mg peanut flour (1000 mg cumulatively) with either no or mild symptoms.
次要结局
- Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 4,000 mg of Peanut Flour.(after 7-8 wks of desensitization)
研究者
Lynda Schneider
Associate Professor
Boston Children's Hospital
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
Xolair Treatment for Milk Allergic ChildrenMilk AllergyNCT00968110Boston Children's Hospital10
已完成
1 期
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical TrialPeanut AllergyFood AllergyNCT01781637Boston Children's Hospital36
已完成
早期 1 期
Oral Peanut Immunotherapy for Peanut Allergic PatientsPeanut HypersensitivityNCT01891136University of North Carolina, Chapel Hill36
已完成
2 期
Peanut Allergy Oral Immunotherapy DesensitizationPeanut AllergyNCT01601522Hamilton Health Sciences Corporation43
已完成
1 期
Sublingual Immunotherapy for Peanut Allergy and Induction of TolerancePeanut HypersensitivityFood HypersensitivityPeanut AllergyFood AllergyNCT01373242University of North Carolina, Chapel Hill54